Cancer Therapies including PD-1/PD-L1 Inhibitors, etc. Being the "Hottest"
The 2018 Research Fronts report has recently been released jointly by the Institutes of Science and Development, Chinese Academy of Sciences, National Science Library, Chinese Academy of Sciences, and Clarivate Analytics together with 2018 Research Front Hotness Indexes report, which includes top 10 research fronts in clinical medicine and 11 emerging research fronts in clinical medicine (Table I). Here, I’d like to interpret points therein closely linked with the pharmaceutical industry one by one.
|
No. |
Top 10 research fronts in clinical medicine |
11 emerging research fronts in clinical medicine |
|
1 |
Intensive blood-pressure control |
Novel Synthetic Opioids Epidemic |
|
2 |
F-18-labeled tau tracers positron emission tomography in Alzheimer’s disease |
BCL-2 inhibitor: Venetoclax in relapsed or refractory Chronic Lymphocytic Leukaemia |
|
3 |
Brain gadolinium deposition after administration of gadolinium-based contrast agents |
Effect of FOLFIRI chemotherapy combined with Cetuximab or Bevacizumab in patients with KRAS Wild-Type Metastatic Colorectal Cancer |
|
4 |
Efficacy and safety of infliximab biosimilar CT-P13 |
Long Noncoding RNAs as biomarkers in human cancer progression and prognosis |
|
5 |
Neuroendocrine tumors |
Rotavirus mortality estimation and efficacy of Rotavirus Vaccine |
|
6 |
Artificial pancreas closed-loop control in Diabetes Mellitus |
Clinical scales to identify Acute Ischemic Stroke patients with Large Artery Occlusion |
|
7 |
Outcomes of drug-eluting bioresorbable scaffolds in patients with Coronary Artery Disease |
Clinical trials of PD-1/PD-L1 Inhibitors for cancer patients |
|
Radionuclides-labeled PSMA PET therapy for Castration-Resistant Prostate Cancer |
Immune inhibitors for Atopic Dermatitis |
|
|
9 |
Efficacy and safety of Nintedanib in Idiopathic Pulmonary Fibrosis |
Effect of Early Goal-Directed Therapy (EGDT) on prognosis of Septic Shock |
...









(All Rights Reserved)